BWM
RVNC

BerganKDV Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

BerganKDV Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$962 Hold
38
– – ﹤0.01% 759
2023
Q1 		$1.22K Hold
38
– – ﹤0.01% 884
2022
Q4 		$701 Hold
38
– – ﹤0.01% 915
2022
Q3 		$1K Buy
+38
New +$771 ﹤0.01% 944

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BerganKDV Wealth Management's RVNC Position: Q2 2023 in Review

BerganKDV Wealth Management held its Revance Therapeutics, Inc. (RVNC) position steady in Q2 2023 at 38 shares worth $962. The position accounts for ﹤0.01% of the portfolio, ranked #759.

BerganKDV Wealth Management first reported a position in RVNC in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.22K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • BerganKDV Wealth Management held 38 shares of Revance Therapeutics, Inc. worth $962 as of Q2 2023.
  • BerganKDV Wealth Management left its Revance Therapeutics, Inc. share count unchanged in Q2 2023.
  • Revance Therapeutics, Inc. made up ﹤0.01% of BerganKDV Wealth Management's portfolio in Q2 2023, its #759 holding.
  • BerganKDV Wealth Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and has held it in 4 quarters since.
  • BerganKDV Wealth Management's Revance Therapeutics, Inc. position peaked at $1.22K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.